Physician profile
Chenwi M Ambe
NPI 1942325832
$4,600.40
in general payments reported to CMS, 2019-2025
13 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.63 · 2020: $130 · 2021: $169 · 2022: $283 · 2023: $370 · 2024: $3,471 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,049 · Food and Beverage: $1,858 · Gift: $23.73 · Education: $23.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,048.63 |
| Food and Beverage | $1,858.21 |
| Gift | $23.73 |
| Education | $23.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,790.53 | 2023-2025 | Da Vinci Surgical System |
| Becton, Dickinson and Company | $820.88 | 2024 | Phasix Mesh |
| Integra Lifesciences Corporation | $331.96 | 2020-2023 | Codman Hakim, Cusa Clarity, Codman Certas |
| Abbvie INC. | $198.03 | 2019-2025 | |
| Dilon Technologies, INC. | $128.91 | 2023-2024 | Hemoblast Bellows |
| Ethicon US, LLC | $93.36 | 2020-2024 | Megadyne, Echelon Endopath, Harmonic |
| Tela Bio, INC. | $60.95 | 2024 | Ovitex 2s |
| Smith+Nephew, INC. | $49.04 | 2019-2021 | |
| Davol INC. | $40.86 | 2023-2025 | Phasix Mesh |
| Vertex Pharmaceuticals Incorporated | $37.31 | 2025 | |
| Stryker Corporation | $19.93 | 2019 | |
| Bioptics, INC. | $16.67 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chenwi Ambe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.